- Trials with a EudraCT protocol (58)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
58 result(s) found for: Molecular oxygen.
Displaying page 1 of 3.
EudraCT Number: 2017-003714-68 | Sponsor Protocol Number: 1744/2017 | Start Date*: 2017-11-15 | ||||||||||||||||
Sponsor Name:Medical University of Vienna | ||||||||||||||||||
Full Title: Effect of Supplemental Oxygen on Perioperative Brain Natriuretic Peptide Concentration in Cardiac Risk Patients - A prospective randomized clinical trial | ||||||||||||||||||
Medical condition: Evaluation of the effect of 80% versus 30% supplemental oxygen administration during major abdominal surgery on postoperative brain natriuretic peptide concentration. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-005299-32 | Sponsor Protocol Number: OPHT-110912 | Start Date*: 2013-01-24 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | |||||||||||||
Full Title: Effect of breathing 100% oxygen on brain metabolites measured by 7-Tesla MRI | |||||||||||||
Medical condition: brain metabolism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002130-72 | Sponsor Protocol Number: 8845 | Start Date*: 2016-08-08 |
Sponsor Name:Division of Thoracic and Hyperbaric Surgery, Medical University Graz | ||
Full Title: Hyperbaric Oxygenation (HBO) in traumatic spinal cord injury. | ||
Medical condition: We want to investigate the effect of hyperbaric oxygen therapy on the neurological and clinical outcome following traumatic injury of the spinal cord. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-004679-11 | Sponsor Protocol Number: 0604 | Start Date*: 2020-04-21 |
Sponsor Name:Division of Thoracic and Hyperbaric Surgery, Medical University Graz | ||
Full Title: Hyperbaric Oxygenation (HBO) in traumatic spinal cord injury - prospective study with 100 patients. | ||
Medical condition: We want to investigate the effect of hyperbaric oxygen therapy on the neurological and clinical outcome following traumatic injury of the spinal cord. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-002152-26 | Sponsor Protocol Number: ISRCTN86894066 | Start Date*: 2009-01-20 | |||||||||||
Sponsor Name:The Royal Marsden Foundation Trust and The Institute of Cancer Research | |||||||||||||
Full Title: Randomised double-blind controlled phase III trial of hyperbaric oxygen therapy in patients suffering long-term adverse effects of radiotherapy for pelvic cancer | |||||||||||||
Medical condition: Chronic radiation-induced gastrointestinal symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000556-19 | Sponsor Protocol Number: 6011 | Start Date*: 2021-10-20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Rigshospitalet, Department of Anaesthesia, Centre of Head and Orthopaedics | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Comparing Restrictive vs. Liberal Oxygen Strategies for Trauma Patients: The TRAUMOX2 Trial | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Victims of trauma are often healthy individuals prior to the incident, but acquire numerous complications including sepsis and pulmonary complications and diminished quality of life after trauma. W... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001891-14 | Sponsor Protocol Number: Heparin-SARS-CoV2 | Start Date*: 2020-05-04 |
Sponsor Name:Fundación Neumosur | ||
Full Title: Impact of the use of low molecular weight heparins (LMWH), at prophylactic versus intermediate doses, on SARS-CoV2 infection (COVID-19) | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003913-21 | Sponsor Protocol Number: NL78575.018.21 | Start Date*: 2022-07-20 | ||||||||||||||||||||||||||
Sponsor Name:Amsterdam UMC | ||||||||||||||||||||||||||||
Full Title: A Prospective, Open-label Pilot Study to Evaluate Effector mechanisms of Hyperbaric Oxygen Therapy in Patients with Moderate-to-Severe Ulcerative Colitis: The PARADOX study | ||||||||||||||||||||||||||||
Medical condition: Ulcerative colitis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001995-13 | Sponsor Protocol Number: BREATH-19 | Start Date*: 2020-05-15 | |||||||||||
Sponsor Name:Fundación SEIMC-GESIDA | |||||||||||||
Full Title: A multicentre, open-label clinical trial to evaluate the effectiveness and safety of intravenous tocilizumab for treating patients with COVID-19 pneumonia: the BREATH-19 Study | |||||||||||||
Medical condition: COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003125-39 | Sponsor Protocol Number: TRI-08892 | Start Date*: 2020-10-12 |
Sponsor Name:Thrombosis Research Institute | ||
Full Title: Early thromboprophylaxis in COVID-19 (ETHIC trial): an open label, randomized phase IIIb trial of community-based prophylactic low-molecular-weight heparin (LMWH) versus standard of care (no enoxap... | ||
Medical condition: Confirmed diagnosis of SARS-CoV-2 with symptomatic COVID-19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-002023-11 | Sponsor Protocol Number: 53718678RSV3001 | Start Date*: 2021-02-16 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (≥28 Days to ≤5 Years of Age) and Subsequently in Neonates (... | |||||||||||||
Medical condition: Respiratory Syncytial Virus | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) DE (Prematurely Ended) SE (Completed) CZ (Completed) HU (Completed) BE (Completed) PL (Completed) Outside EU/EEA EE (Completed) LV (Completed) SK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002009-85 | Sponsor Protocol Number: CF101-241COVID-19 | Start Date*: 2021-08-12 |
Sponsor Name:Can-Fite BioPharma, Ltd. | ||
Full Title: Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Pilot Trial | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BG (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001450-22 | Sponsor Protocol Number: MESCEL-COVID19 | Start Date*: 2020-04-29 | |||||||||||
Sponsor Name:Fundación de Investigación del Hospital Infantil Universitario Niño Jesús | |||||||||||||
Full Title: Phase II Clinical Trial to explore the efficacy of allogeneic mesenchymal cells from umbilical cord tissue in patients with severe pulmonary involvement by COVID-19. | |||||||||||||
Medical condition: Severe pulmonary involvement by COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001972-13 | Sponsor Protocol Number: COVID-19HD | Start Date*: 2020-05-21 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA | |||||||||||||
Full Title: Randomised controlled trial comparing efficacy and safety of high versus low low-molecular weight heparin dosages in hospitalised patients with severe COVID-19 pneumonia and coagulopathy not requir... | |||||||||||||
Medical condition: Hospitalized patients with severe COViD-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004880-29 | Sponsor Protocol Number: HUB-INF-RADICAP | Start Date*: 2019-10-02 | |||||||||||
Sponsor Name:Dr. Jordi Carratalà Fernández (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge | |||||||||||||
Full Title: Phase IV randomized, controlled, open and multicentre clinical trial with two parallel groups, to assess the impact of integral molecular tests in the antimicrobial use in community-acquired pneumo... | |||||||||||||
Medical condition: Community-acquired pneumonia (CAP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002537-15 | Sponsor Protocol Number: R10933-10987-COV-2066 | Start Date*: 2020-10-06 | ||||||||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS CoV 2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19 | ||||||||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-003936-25 | Sponsor Protocol Number: RLX0120 | Start Date*: 2020-10-31 | |||||||||||
Sponsor Name:DOMPé FARMACEUTICI S.P.A. | |||||||||||||
Full Title: Multicenter, adaptive, randomized, placebo-controlled, double blind, parallel-group Phase 2/3 trial, to study efficacy and safety of two doses of raloxifene in adult paucisymptomatic COVID-19 patie... | |||||||||||||
Medical condition: Adult paucisymptomatic COVID-19 patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002612-31 | Sponsor Protocol Number: MANTICO | Start Date*: 2021-05-25 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Adaptive, randomized, placebo-controlled trial to evaluate the efficacy of monoclonal antibodies in outpatients with mild or moderate COVID-19 (MANTICO) | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001862-56 | Sponsor Protocol Number: 64041575RSV2004 | Start Date*: 2018-01-09 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (... | |||||||||||||
Medical condition: Respiratory syncytial virus infection | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) FI (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) IE (Prematurely Ended) PT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001682-36 | Sponsor Protocol Number: MSV_COVID | Start Date*: 2020-04-13 | |||||||||||
Sponsor Name:CITOSPIN S.L. | |||||||||||||
Full Title: Double-blind, placebo-controlled phase I/II clinical trial to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSV®-allo) in acute respiratory failure in patients with COVID-1... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
